(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.74%) $83.23
(-1.16%) $1.619
(-0.03%) $2 346.60
(-0.16%) $27.49
(0.09%) $922.90
(-0.10%) $0.934
(-0.02%) $11.02
(-0.14%) $0.799
(0.00%) $92.17
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.23%
Live Chart Being Loaded With Signals
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells...
Stats | |
---|---|
今日成交量 | 223 279 |
平均成交量 | 39 265.00 |
市值 | 185.82M |
EPS | $0 ( 2024-03-27 ) |
下一个收益日期 | ( $0 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.780 |
ATR14 | $0.0300 (1.20%) |
Cellectis S.A. 财务报表
Annual | 2022 |
营收: | $19.17M |
毛利润: | $17.40M (90.76 %) |
EPS: | $-2.17 |
FY | 2022 |
营收: | $19.17M |
毛利润: | $17.40M (90.76 %) |
EPS: | $-2.17 |
FY | 2021 |
营收: | $57.29M |
毛利润: | $25.93M (45.26 %) |
EPS: | $-1.910 |
FY | 2020 |
营收: | $73.95M |
毛利润: | $37.67M (50.95 %) |
EPS: | $-1.910 |
Financial Reports:
No articles found.
Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。